Fig. 6: Effects of SLC7A11 on cellular metabolism.
From: Super-enhancers mediates SLC7A11 via FOXA1 to regulate disulfidptosis in prostate cancer
A, B Cysteine level in PC-3 and DU145 cells with varying SLC7A11 expression levels. C, D NADP⁺/NADPH ratio in SLC7A11-overexpressing (OE) cells under glucose-deprived conditions (−Glc) at different time points. E Reducing and non-reducing Western blot analysis showing the migration patterns of cytoskeletal proteins in SLC7A11-OE cells under different culture conditions. F–H Flow cytometry analysis of apoptosis in DU145-OE and PC-3-OE cells under glucose and/or cystine deprivation. I, J BAY-876 significantly inhibits glucose uptake in DU145 and PC-3 cells. K, L BAY-876 treatment leads to increased NADPH consumption, as reflected by elevated NADP⁺/NADPH ratios in DU145 and PC-3 cells. M–O In vivo, BAY-876 treatment results in significantly reduced tumor volume, weight, and growth rate in DU145-OE xenografts compared to DU145-NC controls. P Immunohistochemistry reveals a marked reduction in Ki67-positive area in DU145-OE tumors compared to DU145-NC. Q–S BAY-876 also significantly suppresses tumor volume, weight, and growth rate in PC-3-OE xenografts relative to PC-3-NC controls. T Immunohistochemical staining indicates decreased Ki67 expression in PC-3-OE tumors compared to PC-3-NC tumors.
